Utility or futility of Interleukin 2 receptor antagonist ( IL 2 RA ) induction in kidney transplants‐ the devil is in the detail

Authors:
Publisher website
Google Scholar
Abstract
Induction therapy is used routinely in kidney transplantation and has been recommended by the 2009 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline as a level 1A recommendation (1). However, which agent should be used for induction and in which patient remains a matter of debate. Induction agents currently in use include depleting (usually, polyclonal anti‐thymocyte globulin derived from rabbit –rATG) or non depleting (Interleukin 2 receptor antagonists ‐ IL2RA) agents.